All In Biotech

Drug Trial Radar · NCT06565650

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

216

Actual

Start

Jul 31, 2024

Primary completion

Nov 2025

Study completion Nov 2025

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months

Conditions

  • Dry Eye

Interventions

  • MieboDrug

    100% perfluorohexyloctane

  • SalineDrug

    0.6% sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in ECDTime frame: Assessed at Month 3 and Month 12 Visits

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Site 101

    Glendale, California

  • Site 112

    Murrieta, California

  • Site 102

    Newport Beach, California

  • Site 109

    Rancho Cordova, California

  • Site 106

    Torrance, California

  • Site 113

    Delray Beach, Florida

  • Site 107

    Morrow, Georgia

  • Site 105

    Carmel, Indiana

  • Site 110

    Kansas City, Missouri

  • Site 104

    St Louis, Missouri

  • Site 108

    Asheville, North Carolina

  • Site 103

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.